Skip to content
value.today

Inmed Pharmaceuticals Inc.

INM
$9 Mmarket cap on Oct 29, 2026+196.7% since Jan 2024
Compare
World rank
#26,125
Revenue
—
For year ending June-2026
Net income
$-13 M
SEC filing
Employees
6
As of September 1, 2026
SEC filing

Inmed Pharmaceuticals Inc. in brief

Inmed Pharmaceuticals Inc. is a listed company in the Biotechnology industry, based in Vancouver, Canada. Its market value was $9 M on 29 October 2026, which makes it the 26,125th largest listed company in the world and the 1,407th largest in Canada on this site. It employs about 6 people and Eric A. Adams is its chief executive. Its shares trade under the symbol INM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Inmed Pharmaceuticals Inc.

We are a pharmaceutical drug development company with a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. Our research efforts target the treatment of diseases with high unmet medical needs. On March 4, 2026, the InMed Board ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica’s commercial operations business segment, which constitutes the only revenue-generating commercial operations of InMed. As of June 30, 2026, BayMedica had wound down all of its operating activities, and had two remaining employees who departed on July 31, 2026, as well as a commercial lease which will terminate at the end of August. Following the wind down of commercial operations, InMed’s remaining activities have consisted of preclinical development of its Product Candidates, including INM-901 for Alzheimer’s disease, INM-089 for dry Age-related Macular Degeneration or dry AMD, and INM-755 (cannabinol) cream. InMed does not currently intend to devote significant resources to advancing these Product Candidates, and any further development of them would require InMed to obtain additional financing, of which there can be no assurance.

From the company's annual report filed with the US SEC: read the report

Inmed Pharmaceuticals Inc. timeline

2 events, 2018–2025
  1. 2018
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2025
  4. 💰
    Record revenue of $5 million
    FY2025, the highest of the 5 years on record.

Events of Inmed Pharmaceuticals Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$5 M$9 M$14 M$18 M2023202420252026

World rank over time

▲ up 5,302 places since 2022
2022-01-07: #31439#31,43920222024-01-05: #32948#32,94820242026-03-08: #13385#13,38520262026-08-01: #23751#23,75120262026-10-14: #26399#26,39920262026-10-29: #26137#26,1372026

Rank in Canada: #1,403 (Jan 2022) · #1,627 (Jan 2024) · #59 (Mar 2026) · #830 (Aug 2026) · #1,495 (Oct 2026) · #1,407 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
8.2×
Free cash flow yield
-91.0%
Net margin
—
Operating margin
—
Return on equity
-1163.0%
Liabilities / assets
64.7%
Revenue growth
+7.4%
R&D / revenue
57.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jun 2020: revenue —, net income $-9M—FY20Fiscal year ending Jun 2021: revenue $2M, net income $-10M$2MFY21Fiscal year ending Jun 2022: revenue $1M, net income $-19M$1MFY22Fiscal year ending Jun 2023: revenue $4M, net income $-8M$4MFY23Fiscal year ending Jun 2024: revenue $5M, net income $-8M$5MFY24Fiscal year ending Jun 2025: revenue $5M, net income $-8M$5MFY25Fiscal year ending Jun 2026: revenue —, net income $-13M—FY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jun 2026———$-13M—
Jun 2025$5M+7.4%—$-8M-165.2%
Jun 2024$5M+11.1%—$-8M-167.0%
Jun 2023$4M+279.8%$-8M$-8M-192.0%
Jun 2022$1M-42.6%$-19M$-19M-1706.4%
Jun 2021$2M—$-10M$-10M-536.8%
Jun 2020———$-9M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jun 2026$-9M——$-3.12—
Jun 2025$-8M$0M$-8M$-8.36—
Jun 2024$-7M$0M$-7M$-20.14—
Jun 2023$-7M$0M$-7M$-3.25—
Jun 2022$-16M$0M$-16M$-33.17—
Jun 2021$-10M$0M$-10M$-37.96—
Jun 2020$-7M$0M$-7M$-1.71—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue $1M, net income $-3M$1MDec ’24Three months to Mar 2025: revenue $1M, net income $-2M$1MMar ’25Three months to Jun 2025 (from the annual report): revenue $1M, net income $-2M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $-2M$1MSep ’25Three months to Dec 2025: revenue $1M, net income $-2M$1MDec ’25Three months to Mar 2026: revenue —, net income $-3M—Mar ’26Three months to Jun 2026 (from the annual report): revenue —, net income $-6M—Jun ’26Three months to Sep 2026: revenue —, net income $-2M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Inmed Pharmaceuticals Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
—
Net income
$-13 M

For year ending June-2026 · source: SEC filing

Balance sheet

Total assets
$3 M
Total liabilities
$2 M
Total equity
$1 M

As of June-2026

Top 17 institutional investors in Inmed Pharmaceuticals Inc.#

As of Sep 30, 2026
17 institutions held 6.7 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 17 largest institutional investors in Inmed Pharmaceuticals Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Eventide Asset Management, LLC4,354,499New79.26%$6 MNov 13, 2026
2Seven Fleet Capital Management LP1,069,519New19.47%$1 MNov 16, 2026
3Vivo Capital, LLC824,874+26,497 (+3.32%)15.01%$1 MNov 13, 2026
4Ikarian Capital, LLC137,634-107,391 (-43.83%)2.51%$0 MNov 16, 2026
5Venrock Adviser, LLC133,378+100,693 (+308.07%)2.43%$0 MNov 16, 2026
6Jane Street Group, LLC52,947+9,869 (+22.91%)0.96%$0 MNov 12, 2026
7Citadel Advisors LLC42,972+16,888 (+64.74%)0.78%$0 MNov 16, 2026
8Boothbay Fund Management, LLC39,915-34,329 (-46.24%)0.73%$0 MNov 16, 2026
9Seven Grand Managers, LLC25,0000 (0.00%)0.46%$0 MNov 16, 2026
10XTX Topco Ltd19,047New0.35%$0 MNov 16, 2026
11Crestwood Advisors Group, LLC14,9000 (0.00%)0.27%$0 MOct 27, 2026
12Two Sigma Investments, LP11,906New0.22%$0 MNov 16, 2026
13Private Wealth Management Group, LLC5,0000 (0.00%)0.09%$0 MOct 19, 2026
14UBS Group AG3,194New0.06%$0 MNov 10, 2026
15SBI Securities Co., Ltd.3000 (0.00%)0.01%$0 MOct 22, 2026
16Banque Cantonale Vaudoise60 (0.00%)0.00%$0 MNov 12, 2026
17Federation des caisses Desjardins du Quebec20 (0.00%)0.00%$0 MNov 16, 2026

Mutual funds holding Inmed Pharmaceuticals Inc.#

1 funds hold shares worth $0 M. Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Inmed Pharmaceuticals Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC6,495$0 M—<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Inmed Pharmaceuticals Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$1.4 M
50 purchases, 4 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$1.4 M
open market only
Insiders on file
9
since
$895 K-$43$0Feb 2024: bought $30 K (2 trades), sold $0 (0 trades)Feb 24Jul 2024: bought $0 (0 trades), sold $43 (1 trades)JulMay 2026: bought $895 K (9 trades), sold $0 (0 trades)MayJun 2026: bought $219 K (14 trades), sold $0 (0 trades)JunJul 2026: bought $43 K (11 trades), sold $0 (0 trades)JulSep 2026: bought $118 K (3 trades), sold $0 (0 trades)SepOct 2026: bought $86 K (12 trades), sold $0 (0 trades)OctNov 2026: bought $35 K (1 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Inmed Pharmaceuticals Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+2,640$13.10$35 K98,297Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+4$1.320$5956,584Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+1,086$1.320$1 K956,580Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+1$1.320$1955,494Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+984$1.322$1 K955,493Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+8,021$1.330$11 K954,509Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+564$1.330$750946,488Form 4
filed ADAR1 Capital Management, LLC10% ownerBuyindirect+2,256$1.328$3 K945,924Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Inmed Pharmaceuticals Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
63,409
1.2% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-11-11 14:32 UTC, code LUDP, resumed 14:37 UTC
  • 2026-11-09 19:34 UTC, code LUDP, resumed 19:39 UTC
  • 2026-11-09 19:18 UTC, code LUDP, resumed 19:23 UTC
  • 2026-11-09 18:18 UTC, code LUDP, resumed 18:23 UTC
  • 2026-11-09 18:12 UTC, code LUDP, resumed 18:17 UTC

Fails to deliver

  • : 815 shares at $1.62
  • : 12,292 shares at $1.59
  • : 1,626 shares at $1.44
  • : 3,470 shares at $1.36
  • : 738 shares at $1.33

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Inmed Pharmaceuticals Inc. scorecard#

Passes 1 of the 12 checks that could be worked out. Fiscal year 2026; market cap of Oct 29, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median8.2×Price to book 8.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-91.0%Free cash flow is -91.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-3.12 vs -8.36Diluted EPS -3.12 in fiscal 2026 against -8.36 the year before (report's currency).
    • ✗Net income higher than five years earlier-$13 M-$13 M in fiscal 2026 against -$10 M in 2021.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$13 MNet income -$13 M in fiscal 2026.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-173.1%-173.1% in fiscal 2026.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities1.4×Current ratio 1.37 at the end of fiscal 2026.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year326.6%Diluted shares up 326.6% in fiscal 2026.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Inmed Pharmaceuticals Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Inmed Pharmaceuticals Inc.: statements by fiscal year
PeriodTrendFY 2026to Jun 30, 2026FY 2025to Jun 30, 2025FY 2024to Jun 30, 2024FY 2023to Jun 30, 2023FY 2022to Jun 30, 2022FY 2021to Jun 30, 2021FY 2020to Jun 30, 2020
Income statement
Revenue—4.94.64.11.11.9—
Cost of revenue—3.23.52.7r0.5——
Gross profit—1.71.11.40.5——
Research and development3.02.8r3.2r3.77.35.35.8
General and administrative6.75.4r5.8r5.86.94.53.2
Operating expenses128.5r9.39.8r189.99.2
Operating income———−7.9−19−10—
Interest and finance income0.20.20.50.50.10.00.1
Net interest income—————−0.4—
Other non-operating income (expense)——0.50.5r−1.3−0.4—
Income before tax−11−8.7r−7.7−7.9−19——
Income tax——0.00.0———
Income from continuing operations−11−8.7—————
Income from discontinued operations−1.20.5—————
Net income including minority interests———7.919108.9
Net income attributable to shareholders−13−8.2−7.7−7.9−19−10−8.9
Earnings per share, basic-3.12-8.36-20.14r-3.25-33.17-37.96r-1.71
Earnings per share, diluted-3.12-8.36-20.14r-3.25-33.17-37.96r-1.71
Shares, weighted average (basic)4.21.0r0.4r2.40.60.3—
Shares, weighted average (diluted)4.21.0r0.4r2.40.60.3r5.2
Balance sheet
Cash and cash equivalents2.211r6.68.96.27.45.8
Short-term investments0.00.00.00.00.00.00.0
Receivables—0.50.40.30.10.00.0
Inventory—1.01.21.62.5——
Other current assets0.20.3r0.50.50.81.00.4
Current assets2.7138.7119.68.46.3
Property, plant and equipment0.21.01.20.70.90.30.4
Other intangible assets—1.61.81.92.11.11.1
Total assets3.0161214139.87.8
Accounts payable0.90.3r0.00.51.2r2.11.6
Current liabilities2.01.82.02.03.32.21.7
Lease liabilities (non-current)—0.30.60.00.40.20.2
Total liabilities2.02.12.62.03.72.41.9
Retained earnings−130−117−109−101−93−75−65
Shareholders' equity1.1139.2129.17.45.9
Total liabilities and equity3.0161214139.87.8
Shares outstanding5.32.00.4r3.30.70.3r5.2
Cash-flow statement
Depreciation and amortization0.20.20.20.20.20.10.1
Share-based compensation0.10.10.10.3r0.70.61.0
Cash from operating activities−8.6−8.1r−7.0−7.3−16−9.8−7.4
Capital expenditure——−0.0−0.2−0.0−0.0−0.0
Acquisitions, net of cash acquired———−0.5———
Cash from investing activities——−0.0−0.7−0.7−0.03.8
Debt repaid————−0.3——
Shares issued———121712—
Cash from financing activities0.1124.7111511−0.0
Exchange-rate effect on cash—————0.5−0.4
Change in cash——−2.32.7−1.21.6−4.0
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Inmed Pharmaceuticals Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Restructuring 1 · Change in control 2 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 6 · Unregistered share sale 2 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 1

Inmed Pharmaceuticals Inc.: events reported to the SEC
FiledWhat happenedFiling
Change in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changedResults announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Delisting notice8-K
Material agreement8-K
Material agreementShareholder rights changed8-K
Change in controlDirectors and officersMaterial agreement8-K
Material agreementShareholder rights changed8-K
Delisting notice8-K
Restructuring8-K
Shareholder vote8-K
Directors and officers8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Inmed Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2022$6 MPrivate placement after listing$2 to $10 million2equity, optionsSEC
Jun 2022$5 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Oct 2021$4 MIssued in a merger or acquisition$2 to $10 million54equitySEC
Jul 2021$12 MNo. 2$10 to $50 million1equity, optionsSEC
Jan 2018$2 MNo. 1Under $2 million2equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Inmed Pharmaceuticals Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2026–2026
Latest
—
2026-03-04
Inmed Pharmaceuticals Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
Inmed Pharmaceuticals Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Inmed Pharmaceuticals Inc. compares in Biotechnology

  • Market cap$9 M · higher than 9% of 726
  • Revenue growth7.4% · higher than 51% of 438
  • Price / book8.2× · lower than 19% of 534
  • FCF yield-91.0% · higher than 11% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Inmed Pharmaceuticals Inc.🇨🇦$9 M——+7.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending June-2026
Balance sheet:
As of June-2026
Employees:
As of September 1, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Inmed Pharmaceuticals Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Inmed Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Inmed Pharmaceuticals Inc.? Suggest a correction